PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Diagnosis and treatment of neoplastic post-transplant lymphoproliferative disorder following hematopoietic stem cell transplant in β-thalassemia: A pediatric case report.

Abstract Post-transplant lymphoproliferative disorder (PTLD) is the most common form of lymphoproliferation in childhood and is associated with significant morbidity and mortality. In this report we reviewed the case of a pediatric patient who experienced PTLD after allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA)-identical sibling.
PMID
Related Publications

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation.

The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.

A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.

Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases.

The risk factors of post-transplant lymphoproliferative disorders following haploidentical hematopoietic stem cell transplantation.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29384898
OWN - NLM
STAT- MEDLINE
DCOM- 20180209
LR  - 20180209
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 52
DP  - 2017 Dec
TI  - Diagnosis and treatment of neoplastic post-transplant lymphoproliferative
      disorder following hematopoietic stem cell transplant in beta-thalassemia: A
      pediatric case report.
PG  - e9055
LID - 10.1097/MD.0000000000009055 [doi]
AB  - INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is the most
      common form of lymphoproliferation in childhood and is associated with
      significant morbidity and mortality. In this report we reviewed the case of a
      pediatric patient who experienced PTLD after allogeneic hematopoietic stem cell
      transplantation (HSCT) from a human leukocyte antigen (HLA)-identical sibling.
      METHODS: The clinical characteristics, diagnosis, and treatment of PTLD after
      sibling HSCT in a 4-year-old boy with severe beta-thalassemia was retrospectively
      reviewed. RESULTS: Medical records revealed the patient developed a fever and
      superficial lymphadenopathy and soft palate enlargement 8 months post-HSCT.
      Pathologic diagnosis indicated non-Hodgkin lymphoma (B-cell type), which resulted
      in a reduced dose of immunosuppressant and the initiation of chemotherapy
      (administered according to the BFM95 protocol for 2 courses; 4 courses of
      rituximab therapy was also administered). Currently, the patient has been
      disease-free for over 3 years. There are no specific guidelines for the treatment
      of PTLD. The status of stem cell implantation after transplantation, and graft
      versus host disease should be evaluated jointly, and rituximab therapy and
      chemotherapy with BFM-95 may be used for treatment of pediatric PTLD after HSCT. 
      CONCLUSION: The current case represents a unique opportunity to review a
      pediatric patient with beta-thalassemia. The successful treatment of
      post-transplant non-Hodgkin B lymphoma may help other physicians in the
      management of similar pediatric cases.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Zhang, Xiaohong
AU  - Zhang X
FAU - Hao, Wenge
AU  - Hao W
FAU - Xu, Tao
AU  - Xu T
FAU - Liu, Sha
AU  - Liu S
FAU - Jiang, Hua
AU  - Jiang H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (HLA Antigens)
SB  - AIM
SB  - IM
MH  - Child, Preschool
MH  - HLA Antigens
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*diagnosis/etiology/*therapy
MH  - Male
MH  - beta-Thalassemia/complications/*therapy
EDAT- 2018/02/01 06:00
MHDA- 2018/02/10 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/02/10 06:00 [medline]
AID - 10.1097/MD.0000000000009055 [doi]
AID - 00005792-201712290-00006 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(52):e9055. doi: 10.1097/MD.0000000000009055.